The Joint (JYNT)

Search documents
The Joint Corp. (JYNT) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research· 2024-03-12 17:01
The Joint Corp. (JYNT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...
The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?
Zacks Investment Research· 2024-03-12 15:46
The Joint Corp. (JYNT) shares soared 10.1% in the last trading session to close at $13.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.9% gain over the past four weeks.The Joint extended its rally for the second straight day, following the strong fourth-quarter 2023 results released on Mar 7. It reported an adjusted earnings per share of 7 cents, which outpaced the Zacks Consensus Estimate of 3 cents. The top line beat the ...
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
Zacks Investment Research· 2024-03-11 16:11
The Joint Corp. (JYNT) shares have jumped 30% since it reported fourth-quarter 2023 financial results. The strong quarterly results were primarily due to continued organic growth and an increased number of clinics, partially offset by higher expenses.In the quarter under review, it witnessed an adjusted earnings per share of 7 cents, beating the Zacks Consensus Estimate of 3 cents. The bottom line also improved from adjusted earnings of 4 cents per share a year ago.Revenues of The Joint amounted to $30.6 mi ...
The Joint (JYNT) - 2023 Q4 - Earnings Call Transcript
2024-03-08 03:17
Financial Data and Key Metrics Changes - Revenue increased by 16% compared to 2022, reaching $30.6 million in Q4 2023, up $2.9 million or 11% year-over-year [8][44] - Adjusted EBITDA for 2023 was $12.2 million, up 6% from the previous year [8][76] - The company reported a net loss of $11.0 million or $0.75 per share for Q4 2023, compared to a net income of $763,000 or $0.05 per diluted share in Q4 2022 [20][76] - Unrestricted cash at December 31, 2023, was $18.2 million, compared to $9.7 million at the end of 2022 [8][48] Business Line Data and Key Metrics Changes - System-wide sales for all clinics increased by 12% to $488 million in 2023, with same-store sales for clinics open 13 months or more increasing by 4% [34][21] - The company opened 114 clinics in 2023, consisting of 104 franchise and 10 greenfield clinics, compared to 137 clinics opened in 2022 [35] - Monthly memberships contributed 85% of system-wide gross sales, up from 84% in 2022 [7] Market Data and Key Metrics Changes - System-wide sales for all clinics opened for any amount of time in Q4 2023 increased to $133.1 million, up 11% [44] - System-wide comp sales for all clinics open 13 months increased by 5% in Q4 2023 [44] - System-wide comp sales for mature clinics open 48 months or more decreased by 1% [21][44] Company Strategy and Development Direction - The company is focusing on a refranchising strategy to shift the clinic portfolio mix, with an expectation that the majority of corporate clinics will be refranchised [10][39] - Marketing efforts are being enhanced to drive new patient counts and improve existing patient engagement, with a focus on local store marketing [14][42] - The company aims to improve unit economics and increase productivity at both the clinic and corporate levels [52] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about seeing a turn in new patient counts in early 2024, indicating potential improvement in patient engagement [58] - The company acknowledged challenges in attracting new patients and emphasized the importance of retaining existing patients [62] - Management expects to see significant reductions in general and administrative expenses as the refranchising strategy progresses [78] Other Important Information - The company recorded a non-cash valuation allowance of $10.8 million against deferred tax assets due to uncertainties related to refranchising transactions [46] - The Joint was recognized as the number one franchise in chiropractic services by Entrepreneur Magazine [81] Q&A Session Summary Question: Can you provide insight into the refranchising process and interest levels? - Management clarified that broadening the scope of potential buyers is not due to lower interest but to ensure clinics are placed in capable hands [55][82] Question: What are the expectations for same-store sales growth moving forward? - Management noted that same-store sales for mature clinics have seen a slight decline, emphasizing the need for renewed marketing efforts [60][62] Question: How many new franchise licenses are expected to be sold this year? - Management refrained from providing specific guidance but noted that economic conditions have impacted franchise sales [66][68] Question: What are the plans for employee retention in light of industry challenges? - Management highlighted efforts to create an attractive work environment for doctors and maintain strong recruitment channels [100] Question: What is the expected portfolio mix after the refranchising initiative? - Management indicated that the majority of corporate clinics will be refranchised, significantly reducing the percentage of company-owned clinics [102]
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research· 2024-03-08 00:55
The Joint Corp. (JYNT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 133.33%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced a loss of $0.05, delivering a surprise of -225%.Over the last four quarters, the company ha ...
The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results
Newsfilter· 2024-03-07 21:20
- Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter and year ended December 31, 2023. Financial Highlights: Q4 2023 Compared to Q4 2022 Grew revenue 11% to $30.6 million.Recorded net los ...
The Joint (JYNT) - 2023 Q4 - Annual Report
2024-03-07 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission File Number: 001-36724 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware 90-0544160 (State or Other Jurisdiction ...
The Joint (JYNT) - 2023 Q4 - Annual Results
2024-03-06 16:00
EXHIBIT 99.1 The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - _____________________________________ Grew revenue 11% to $30.6 million. Recorded net loss on disposition or impairment of $1.5 million, compared to $50,000. Recorded operating loss of $147,000, compared to operating income of $1.5 million. Recorded ...
The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers
Zacks Investment Research· 2024-03-05 18:06
The Joint Corp. (JYNT) is set to report its fourth-quarter 2023 results on Mar 7, after the closing bell. It is expected to have witnessed increased clinic count and patient visits in the December quarter.Earnings Surprise HistoryThe Joint’s earnings beat the consensus estimate once in the prior four quarters and missed thrice, with the average surprise being 112.2%. This is depicted in the graph below:In the last reported quarter, the franchisor of chiropractic clinics reported adjusted operating loss per ...
The Joint Corp. to Participate in the 36th Annual Roth Conference
Newsfilter· 2024-03-04 12:05
SCOTTSDALE, Ariz., March 04, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that management is scheduled to attend the 36th Annual Roth Conference on March 17th – 19th. The conference is being held at The Ritz Carlton in Dana Point, CA. President and Chief Executive Officer Peter Holt and Chief Financial Officer Jake Singleton will participate in a fireside chat with analyst George Kelly on Tuesday ...